The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease

BMC Complementary and Alternative Medicine

Hyunsu Bae¹  Sungki Jung³  Minkyu Shin¹  Moochang Hong¹  Miran Kim²  Geunhyeog Lee²  Seung Ryel Lee¹  Youngeun Kim¹  Soojin Park¹  Kyoung-Keun Haam¹  Kyung-Hwa Jung¹ 

[1] Department of Physiology, College of Korean Medicine, Kyung Hee University, #1 Hoekidong, Dongdaemoonku, Seoul 130-701, Republic of Korea;Central Research Institute, Hanlim Pharm. Co. Ltd., 1007 Yoobang Dong, Yongin, Kyounggi Do, Republic of Korea;Division of Allergy and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, #1 Hoekidong, Dongdaemoonku, Seoul 130-701, Republic of Korea

关键词: MCP-1;    TNF-α;    IL-6;    Neutrophil;    PM014;    CS;    COPD;   

Others  :  1221013
DOI  :  10.1186/1472-6882-13-219

 received in 2013-04-15, accepted in 2013-08-29,  发布年份 2013

【 摘 要 】

Background

In this study, we evaluated the anti-inflammatory effect of PM014 on cigarette smoke induced lung disease in the murine animal model of chronic obstructive pulmonary disease (COPD).

Methods

Mice were exposed to cigarette smoke (CS) for 2 weeks to induce COPD-like lung inflammation. Two hours prior to cigarette smoke exposure, the treatment group was administered PM014 via an oral injection. To investigate the effects of PM014, we assessed PM014 functions in vivo, including immune cell infiltration, cytokine profiles in bronchoalveolar lavage (BAL) fluid and histopathological changes in the lung. The efficacy of PM014 was compared with that of the recently developed anti-COPD drug, roflumilast.

Results

PM014 substantially inhibited immune cell infiltration (neutrophils, macrophages, and lymphocytes) into the airway. In addition, IL-6, TNF-α and MCP-1 were decreased in the BAL fluid of PM014-treated mice compared to cigarette smoke stimulated mice. These changes were more prominent than roflumilast treated mice. The expression of PAS-positive cells in the bronchial layer was also significantly reduced in both PM014 and roflumilast treated mice.

Conclusions

These data suggest that PM014 exerts strong therapeutic effects against CS induced, COPD-like lung inflammation. Therefore, this herbal medicine may represent a novel therapeutic agent for lung inflammation in general, as well as a specific agent for COPD treatment.

【 授权许可】

   
2013 Jung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370(9589):765-773.
• [2]Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364(9434):613-620.
• [3]Calverley PM, Walker P: Chronic obstructive pulmonary disease. Lancet 2003, 362(9389):1053-1061.
• [4]Corrigan CJ, Kay AB: The roles of inflammatory cells in the pathogenesis of asthma and of chronic obstructive pulmonary disease. Am Rev Respir Dis 1991, 143(5 Pt 1):1165-1168. Discussion 1175–1166
• [5]Antoniu SA: New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011, 6:147-155.
• [6]Jeffery PK: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998, 53(2):129-136.
• [7]Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM: Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993, 147(2):301-306.
• [8]Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM: CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(3 Pt 1):822-826.
• [9]Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al.: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995, 8(8):1398-1420.
• [10]George J, Ioannides-Demos LL, Santamaria NM, Kong DC, Stewart K: Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust 2004, 181(5):248-251.
• [11]Shinozuka N, Tatsumi K, Nakamura A, Terada J, Kuriyama T: The traditional herbal medicine Hochuekkito improves systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2007, 55(2):313-314.
• [12]Calixto JB, Campos MM, Otuki MF, Santos AR: Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004, 70(2):93-103.
• [13]Guo R, Pittler MH, Ernst E: Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006, 28(2):330-338.
• [14]Roh GS, Seo SW, Yeo S, Lee JM, Choi JW, Kim E, Shin Y, Cho C, Bae H, Jung SK, et al.: Efficacy of a traditional Korean medicine, Chung-Sang-Bo-Ha-Tang, in a murine model of chronic asthma. Int Immunopharmacol 2005, 5(2):427-436.
• [15]Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, Jung H, Bae H: Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evidence-based complementary and alternative medicine : eCAM 2012, 2012:769830.
• [16]Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A: Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol 2007, 557(2–3):230-235.
• [17]Cuzic S, Bosnar M, Dominis Kramaric M, Ferencic Z, Markovic D, Glojnaric I, Erakovic Haber V: Claudin-3 and Clara cell 10 kDa protein as early signals of cigarette smoke-induced epithelial injury along Alveolar ducts. Toxicol Pathol 2012, 40(8):1169-1187.
• [18]O’Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, et al.: Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004, 59(10):837-842.
• [19]Costenbader KH, Feskanich D, Mandl LA, Karlson EW: Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119(6):503 e501-509.
• [20]Baka Z, Buzas E, Nagy G: Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009, 11(4):238. BioMed Central Full Text
• [21]Jafari N, Hoppenbrouwers IA, Hop WC, Breteler MM, Hintzen RQ: Cigarette smoking and risk of MS in multiplex families. Mult Scler 2009, 15(11):1363-1367.
• [22]Corpechot C, Chretien Y, Chazouilleres O, Poupon R: Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010, 53(1):162-169.
• [23]Ellis JA, Munro JE, Ponsonby AL: Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49(3):411-425.
• [24]Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A: Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011, 8(2):613-628.
• [25]Husgafvel-Pursiainen K: Genotoxicity of environmental tobacco smoke: a review. Mutat Res 2004, 567(2–3):427-445.
• [26]Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W: Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115(3):829-835.
• [27]Baye J: Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T 2012, 37(3):149-161.
• [28]Bethke TD, Lahu G: High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther 2011, 49(1):51-57.
• [29]Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, et al.: Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 2006, 12(5):574-579.
• [30]Epaud R, Aubey F, Xu J, Chaker Z, Clemessy M, Dautin A, Ahamed K, Bonora M, Hoyeau N, Flejou JF, et al.: Knockout of insulin-like growth factor-1 receptor impairs distal lung morphogenesis. PLoS One 2012, 7(11):e48071.
• [31]Barnes PJ: Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004, 56(4):515-548.
• [32]Huvenne W, Perez-Novo CA, Derycke L, De Ruyck N, Krysko O, Maes T, Pauwels N, Robays L, Bracke KR, Joos G, et al.: Different regulation of cigarette smoke induced inflammation in upper versus lower airways. Respir Res 2010, 11:100. BioMed Central Full Text
• [33]Chung KF: Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001, 34:50s-59s.
• [34]Maestrelli P, Saetta M, Mapp CE, Fabbri LM: Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(10 Pt 2):S76-S80.
• [35]Cosio MG, Hale KA, Niewoehner DE: Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980, 122(2):265-221.
• [36]Kovacs K, Erdelyi K, Hegedus C, Lakatos P, Regdon Z, Bai P, Hasko G, Szabo E, Virag L: Poly(ADP-ribosyl)ation is a survival mechanism in cigarette smoke-induced and hydrogen peroxide-mediated cell death. Free Radic Biol Med 2012, 53(9):1680-1688.
• [37]Demirhan O, Demir C, Tunc E, Nandiklioglu N, Sutcu E, Sadikoglu N, Ozcan B: The genotoxic effect of nicotine on chromosomes of human fetal cells: the first report described as an important study. Inhal Toxicol 2011, 23(13):829-834.
• [38]Nardini M, Finkelstein EI, Reddy S, Valacchi G, Traber M, Cross CE, van der Vliet A: Acrolein-induced cytotoxicity in cultured human bronchial epithelial cells. Modulation by alpha-tocopherol and ascorbic acid. Toxicology 2002, 170(3):173-185.
• [39]Keenan CR, Salem S, Fietz ER, Gualano RC, Stewart AG: Glucocorticoid-resistant asthma and novel anti-inflammatory drugs. Drug Discov Today 2012, 17(17–18):1031-1038.
• [40]Lee TY, Chang HH, Chen JH, Hsueh ML, Kuo JJ: Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats. J Ethnopharmacol 2007, 109(2):318-324.
• [41]Wang YH, Hogan SP: Chinese herbal anti-asthma tea to go! Clin Exp Allergy 2010, 40(11):1590-1592.
• [42]Fan LL, Zhu S, Chen HB, Yang DH, Cai SQ, Komatsu K: Identification of the botanical source of stemonae radix based on polymerase chain reaction with specific primers and polymerase chain reaction-restriction fragment length polymorphism. Biol Pharm Bull 2009, 32(9):1624-1627.
• [43]Xiong D, Yu LX, Yan X, Guo C, Xiong Y: Effects of root and stem extracts of Asparagus cochinchinensis on biochemical indicators related to aging in the brain and liver of mice. Am J Chin Med 2011, 39(4):719-726.
• [44]Sun Y, Zou M, Hu C, Qin Y, Song X, Lu N, Guo Q: Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway. Food Chem Toxicol 2012, 51C:53-60.
• [45]Chang HF, Lin YH, Chu CC, Wu SJ, Tsai YH, Chao JC: Protective effects of Ginkgo biloba, Panax ginseng, and Schizandra chinensis extract on liver injury in rats. Am J Chin Med 2007, 35(6):995-1009.
• [46]Panossian A, Wikman G: Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol 2008, 118(2):183-212.
• [47]Wang H, Li Y: Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol 2006, 534(1–3):194-201.
• [48]Li YJ, Peng JM, Zhang FC: Preparation of human phage antibodies specific for SSA/Ro antigen and its sequence analysis. Zhonghua Yi Xue Za Zhi 2004, 84(22):1904-1908.
• [49]Cui S, Wang M, Fan G: Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Zhonghua Yi Xue Za Zhi 2002, 82(8):538-540.
• [50]Eaves-Pyles T, Murthy K, Liaudet L, Virag L, Ross G, Soriano FG, Szabo C, Salzman AL: Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol 2001, 166(2):1248-1260.
• [51]Liu CL, Cheng L, Ko CH, Wong CW, Cheng WH, Cheung DW, Leung PC, Fung KP, Bik-San Lau C: Bioassay-guided isolation of anti-inflammatory components from the root of Rehmannia glutinosa and its underlying mechanism via inhibition of iNOS pathway. J Ethnopharmacol 2012, 143(3):867-875.
• [52]Hong MH, Kim JH, Na SH, Bae H, Shin YC, Kim SH, Ko SG: Inhibitory effects of Paeonia suffruticosa on allergic reactions by inhibiting the NF-kappaB/I kappaB-alpha signaling pathway and phosphorylation of ERK in an animal model and human mast cells. Biosci Biotechnol Biochem 2010, 74(6):1152-1156.
• [53]Drost EM, MacNee W: Potential role of IL-8, platelet-activating factor and TNF-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. Eur J Immunol 2002, 32(2):393-403.
• [54]Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE: Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57(7):590-595.
• [55]Barnes PJ: Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand) 2004, 50 Online Pub:OL627-OL637.